Angiolab, Inc. (XKON:251280)
South Korea flag South Korea · Delayed Price · Currency is KRW
4,050.00
+50.00 (1.25%)
At close: Aug 18, 2025, 3:30 PM KST
1.25%
Market Cap14.73B
Revenue (ttm)702.62M
Net Income (ttm)-1.19B
Shares Out3.28M
EPS (ttm)-1,356.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume205
Average Volume780
Open4,100.00
Previous Close4,000.00
Day's Range4,050.00 - 4,100.00
52-Week Range3,450.00 - 9,200.00
Beta0.14
RSI60.90
Earnings Daten/a

About Angiolab

Angiolab, Inc., a biotechnology company, develops medicine with angiogenesis inhibitors for treating angiogenesis-related diseases. Its Phase I products consist of AL101-PSO for psoriasis. The company’s Phase II a clinical trial products include AL101- NASH for the treatment of non-alcoholic steatohepatitis; AL101-OME, for otitis media with effusion; and AL102-PDT for periodontitis. Its Phase II clinical trial products comprise AL101-AMD to treat age related muscular degeneration; and AL101-AOB for the treatment of abnormal obesity. In addition... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Country South Korea
Stock Exchange Korea New Exchange
Ticker Symbol 251280
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.